Pistacia integerrima, known in traditional medicine systems for its distinctive leaf galls, is a rich source of flavonoids, steroids, terpenoids and phenolic compounds. Previous pharmacological work has hinted at anti-inflammatory and cytotoxic properties, but the molecular basis of any anticancer effect has remained poorly defined. In the new study, the researchers prepared an ethyl acetate fraction of the plant, a fraction enriched for moderately polar phytochemicals, and tested it against A549 cells, a widely used human lung adenocarcinoma cell line that models NSCLC. The choice of fraction was deliberate: ethyl acetate extracts typically concentrate flavonoids such as kaempferol, quercetin and luteolin, along with the phytosterol beta-sitosterol, all of which have been implicated in anticancer activity in earlier literature.

The cytotoxic results were striking. In the MTT assay, a colorimetric test that measures metabolic activity as a proxy for cell viability, the ethyl acetate fraction produced significant, dose-dependent killing of A549 cells, with statistically robust effects at a concentration of 100 micrograms per millilitre (p < 0.0001). In other words, as the dose increased, progressively fewer cancer cells survived, a dose-response relationship that is a hallmark of genuine cytotoxic activity rather than experimental noise. The team then examined whether the fraction could stop cancer cells from replicating over longer periods using a colony formation assay, which tests the ability of individual cells to divide repeatedly and establish new colonies, a key measure of proliferative capacity.

Colony formation collapsed after treatment. The ethyl acetate fraction reduced colony formation to just 18.41 percent of control levels, a statistically significant decrease (p < 0.002) indicating that surviving cells had lost much of their ability to seed new populations. This distinction matters clinically: a drug that merely slows growth may delay tumour expansion, but one that erodes clonogenic capacity strikes at the self-renewing behaviour that drives relapse. The researchers interpret the combined cytotoxicity and anti-clonogenic data as evidence that the plant fraction attacks fundamental proliferative machinery in NSCLC cells rather than exerting a transient, non-specific toxic effect.

Perhaps more important for metastasis, the fraction also crippled the migratory behaviour of the cancer cells. Using two complementary assays, the wound healing assay, in which a scratch is made across a confluent cell layer and the rate of closure is measured, and the Transwell migration assay, in which cells are challenged to move through a porous membrane, the team showed that treated A549 cells migrated markedly less than untreated controls (p < 0.01). Migration is the cellular behaviour that underpins invasion and metastatic spread, the processes responsible for most cancer deaths. Suppressing it suggests the phytochemicals may interfere with the epithelial-mesenchymal transition and the extracellular matrix remodelling programmes that lung tumours exploit to colonise distant tissues.

To understand what was happening at the molecular level, the researchers turned to proteomic profiling with the Human XL Oncology protein array, a platform that simultaneously quantifies dozens of cancer-relevant proteins. Treatment with the ethyl acetate fraction significantly downregulated three proteins: endoglin (CD105), kallikrein-related peptidase 5 (KLK5) and matrix metalloproteinase-2 (MMP-2). Each of these tells a coherent story. Endoglin is a co-receptor in the TGF-beta signalling pathway that promotes angiogenesis, the formation of new blood vessels that feed tumours. KLK5 is a protease associated with tumour progression, and MMP-2 degrades the extracellular matrix, clearing a physical path for invading cells. Their coordinated downregulation indicates that the plant fraction suppresses both the angiogenic and metastatic signalling networks that NSCLC depends on for spread.

The team then asked which individual phytochemicals might be responsible, and against which protein targets they act. Molecular docking, a computational technique that predicts how small molecules fit into the binding pockets of proteins, revealed favourable binding affinities for the major Pistacia integerrima compounds against several oncogenic targets central to NSCLC biology. Kaempferol bound AKT1 with a docking score of -7.6 kcal/mol, while beta-sitosterol showed strong affinity for PI3K at -9.4 kcal/mol, quercetin engaged KRAS at -8.5 kcal/mol, and luteolin docked to MMP9 at -8.1 kcal/mol. These are not arbitrary targets. The PI3K/AKT1 axis is a master regulator of cell survival and proliferation that is frequently hyperactivated in lung cancer, KRAS is one of the most notorious oncogenes in NSCLC and has historically been considered nearly undruggable, and MMP9 drives matrix degradation and invasion.

Docking scores alone can be misleading, because a molecule may fit well in a static protein structure yet fail to remain bound in the dynamic environment of the cell. To address this, the researchers ran molecular dynamics simulations, which track the physical motion of atoms over time using the laws of classical mechanics. The kaempferol-AKT1 complex remained structurally stable throughout a 100-nanosecond simulation, with root mean square deviation and fluctuation analyses indicating that the ligand stayed anchored in the binding pocket without destabilising the protein fold. This kind of sustained stability strengthens the argument that kaempferol is a plausible direct modulator of AKT1 rather than an artefact of the docking algorithm, and it provides a structural starting point for medicinal chemists interested in optimising flavonoid-based AKT inhibitors.

Taken together, the study weaves a consistent narrative from cell culture to proteomics to computational structural biology. A plant fraction rich in flavonoids and phytosterols kills NSCLC cells, blocks their ability to form new colonies, suppresses their migration, and pushes cancer-relevant proteins away from an angiogenic and metastatic state, all while its principal constituents show computationally predicted and dynamically stable interactions with the PI3K/AKT1/KRAS signalling core and matrix metalloproteinases. The authors conclude that Pistacia integerrima bioactives exhibit significant anti-proliferative, anti-migratory and anti-metastatic activities in vitro, providing a scientific rationale for identifying newer promising candidates for NSCLC.

Important caveats remain. All of the experimental evidence comes from a single cell line in vitro, and the concentrations used, particularly the 100 micrograms per millilitre dose in the cytotoxicity assay, are far removed from anything a patient could achieve through an extract or supplement. The docking and dynamics work, however rigorous, generates hypotheses about direct target engagement that still need confirmation with techniques such as surface plasmon resonance, cellular thermal shift assays or kinase activity measurements. No animal data or pharmacokinetic information exists yet, and the fraction itself is a complex mixture whose active constituents and their relative contributions have not been disentangled. Nevertheless, the convergence of phenotypic, proteomic and computational evidence makes Pistacia integerrima a credible candidate for further preclinical development, and it adds to a growing body of work suggesting that flavonoids such as kaempferol and quercetin, and phytosterols such as beta-sitosterol, deserve systematic evaluation as leads against some of the most stubborn signalling pathways in lung cancer. As the search for new weapons against NSCLC intensifies, an old medicinal tree may yet yield distinctly modern drug candidates.

Subject of Research: Anticancer activity of Pistacia integerrima phytochemicals against non-small cell lung cancer via PI3K, AKT1 and KRAS signalling

Article Title: Proteomic regulation of anti-proliferative and anti-migratory activity by potent phytochemicals from Pistacia integerrima J.L. Steward Ex Brandis via PI3K, AKT1, and KRAS for Lung Cancer

Article References: Jamwal, A., Paudel, K., Dua, K., Kulkarni, M. P., Mujwar, S., Dhiman, S., Dalwal, V., Negi, P., & Goyal, R. (2026). Proteomic regulation of anti-proliferative and anti-migratory activity by potent phytochemicals from Pistacia integerrima J.L. Steward Ex Brandis via PI3K, AKT1, and KRAS for Lung Cancer. Molecular Biology Reports, 53(1), Article 1571. https://doi.org/10.1007/s11033-026-12743-5

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12743-5

Keywords: non-small cell lung cancer, Pistacia integerrima, A549 cells, PI3K/AKT1 signalling, KRAS, molecular docking, molecular dynamics simulation, flavonoids, kaempferol, quercetin, MMP-2, anti-migratory activity

The exploration begins with a gene expression analysis drawn from the RNA sequencing dataset GSE107011, which involved a variety of differentiated T cell subsets including CD4 TEMRA, CD8 TEM, and γδ T cells. The striking finding was the anticorrelated expression of KLRG1 and PD-1. While PD-1 is widely recognized as a marker of T cell exhaustion, KLRG1 is associated with more functionally competent T cell populations. The investigation into this dynamic offers potential for therapeutic strategies that leverage the strengths of both markers.

Given the importance of T cells in combating cancer, the notion that they can either be activated or rendered ineffective based on surface markers is pivotal. KLRG1+ T cells often exhibit a higher proficiency in antitumor activity; however, in typical therapeutic regimens, the overwhelming focus on inhibiting PD-1 has overshadowed the potential benefits of also targeting KLRG1. This imbalance in research focus could be a missed opportunity in the quest for effective cancer therapies.

As researchers delve deeper into the role of KLRG1 in different T cell populations, the data reveals that KLRG1+ T cells have distinct functional capabilities compared to their PD-1+ counterparts. In fact, investigations into human blood CD8+ T cell surface expression indicate that KLRG1 is highly expressed in effector T memory (TEM) and effector memory re-expressing CD45RA (TEMRA) cells. This contrasts with the expression patterns of PD-1, thus reinforcing the notion that these two markers operate in opposite directions, particularly in the context of immune response.

The implications of such findings are profound, especially when considering the treatment of non-small cell lung cancer (NSCLC). In this distinct subgroup of cancer, the characterization of PD-1+ CD8+ tumor infiltrating lymphocytes unfolds a new understanding of T cell functionality. The study underscores that not all PD-1+ TILs are created equal; the analysis demonstrates that a subset of these cells, specifically PD-1-high TILs, is not representative of the more differentiated and effector-based TEMRA phenotype.

Furthermore, this revelation hints at a critical aspect of immunotherapy: the need to develop multi-targeted approaches. Traditional therapies that focus singularly on PD-1 may inadvertently overlook the mechanistic intricacies that KLRG1 presents. The study advocates for a dual blockade of PD-1 and KLRG1 as a potentially more fruitful approach in enhancing T cell efficacy against tumors.

The research team, led by Dr. Steven A. Greenberg of Harvard Medical School, emphasizes that existing therapeutic strategies should evolve towards utilizing both KLRG1 and PD-1 markers in tandem to maximize treatment effectiveness. The findings indicate that T cells expressing KLRG1 could possess a unique capacity for tumor eradication which, if harnessed alongside PD-1 blockade, might yield supra-additive benefits.

Overall, the study is timely and relevant as the field of immuno-oncology seeks innovative ways to combat increasingly resistant cancers. It challenges the singular narrative of PD-1 as the sole target in T cell modulation, opening a dialogue around the benefits of integrating KLRG1 into immunotherapeutic regimens. This new understanding not only enriches current knowledge but also lays the groundwork for clinical trials that could substantively shift how cancer treatments are approached in the future.

Moreover, the implications for patient outcomes could be substantial, particularly for those afflicted with high-burden malignancies such as melanoma, colorectal cancer, and NSCLC. As the scientific community comes to terms with the intricacies surrounding KLRG1 and PD-1, there lies a future where combination therapies could leverage the unique properties of tumor-infiltrating lymphocytes, creating a landscape where cancer’s resilience is effectively challenged.

This study represents a critical step in understanding the balance and interplay of T cell inhibitory receptors and their roles in cancer. Moving forward, it beckons further investigation into the molecular pathways connecting KLRG1 and PD-1 and illuminates new avenues for therapeutic interventions that are desperately needed in the fight against cancer.

Given the current trajectory of research, the targeting of dual inhibitory receptors like KLRG1 and PD-1 could very well redefine the standards of care in immunotherapy. As studies continue to unravel the complexities of immune responses against cancer, this newfound knowledge will likely play a vital role in the development of innovative treatment strategies that not only improve efficacy but also carve out a path toward durable remissions for patients facing challenging prognoses.

In conclusion, harnessing the insights gathered from this research could represent a paradigm shift in cancer immunotherapy, one that champions a more nuanced understanding of immune cell functionality in the tumor microenvironment. As scientists strive to bridge the gap between basic research findings and clinical applications, the exciting potential of KLRG1 and PD-1 dual-targeting emerges as a provocative and promising landscape in modern oncology.

Subject of Research: Immunotherapy targeting KLRG1 and PD-1 in cancer treatment
Article Title: Anti-correlation of KLRG1 and PD-1 expression in human tumor CD8 T cells
News Publication Date: January 20, 2025
Web References: Oncotarget
References: DOI: 10.18632/oncotarget.28679
Image Credits: © 2025 Greenberg

Keywords: KLRG1, PD-1, cancer immunotherapy, T cells, combination therapy, non-small cell lung cancer, antigen-exhaustion, tumor microenvironment, checkpoint inhibitors, cancer treatment research.